Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.

Abstract excerpt

Somatic mutations binding to the patient's MHC and recognized by autologous T cells (neoepitopes) are ideal cancer vaccine targets. They combine a favorable safety profile due to a lack of expression in healthy tissues with a high likelihood of immunogenicity, as T cells recognizing neoepitopes are not shaped by central immune tolerance. Proteins mutated in cancer (neoantigens) shared by patients have been...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antigenic Variation
• Share to Antigens, Neoplasm